🧫
NP137 antibody treatment effects on EMT and metastasis in mouse SCC
active
experiment
Created: 2026-04-10T14:41:33
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-a6cf73af-6b06-42d2-9313-8f4ee944f7b7
🧫 Experiment Protocol
ValidationSkin squamous cell carcinomaNTN1Primary mouse modelproposed
This experiment investigated the therapeutic effects of NP137, a netrin-1-blocking monoclonal antibody, on epithelial-to-mesenchymal transition and metastasis in the mouse skin SCC model. The study administered NP137 to mice with SCC and evaluated multiple outcomes including the proportion of EMT tumor cells, metastasis formation, and chemotherapy sensitivity. Results showed that NP137 treatment decreased EMT tumor cell proportions, reduced metastases, and increased sensitivity to chemotherapy, demonstrating the therapeutic potential of targeting netrin-1 in cancer treatment.
PRIMARY OUTCOME
Proportion of EMT tumor cells, metastasis number, chemotherapy sensitivity
EXPECTED OUTCOMES
Decreased EMT, reduced metastases, increased chemotherapy sensitivity
SUCCESS CRITERIA
Significant reduction in EMT tumor cells and metastases with improved treatment response
PROTOCOL
Administration of NP137 monoclonal antibody to mice with skin SCC, followed by assessment of EMT markers, metastasis counting, and chemotherapy response
LINKED HYPOTHESES
Source: PMID 37532929 ↗
🧫 Experiment Extras
PATHWAY
Netrin-1 signaling pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.